Human Immunodeficiency Virus 1 Post-attachment Fusion Inhibitor [EPC]

540 reported adverse events

Drugs of this class: IBALIZUMAB

These side effects are most commonly reported by patients taking drugs of the Human Immunodeficiency Virus 1 Post-attachment Fusion Inhibitor [EPC] class:

# Side effect Count
0 PRODUCT DOSE OMISSION ISSUE 45
1 VIRAL LOAD INCREASED 45
2 DRUG INEFFECTIVE 44
3 RASH 43
4 HOSPITALISATION 36
5 FATIGUE 30
6 OFF LABEL USE 30
7 DIARRHOEA 28
8 NAUSEA 26
9 DEATH 25
See all common reactions for Human Immunodeficiency Virus 1 Post-attachment Fusion Inhibitor [EPC]

Drugs of the Human Immunodeficiency Virus 1 Post-attachment Fusion Inhibitor [EPC] class are most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 BLOOD HIV RNA 4 0.0769
1 CONGENITAL HIV INFECTION 2 0.0513
2 ANAL CANCER RECURRENT 1 0.0476
3 PRODUCT USE IN UNAPPROVED THERAPEUTIC ENVIRONMENT 11 0.0126
4 T-LYMPHOCYTE COUNT DECREASED 8 0.0117
5 VIRAL LOAD INCREASED 45 0.0116
6 GENOTYPE DRUG RESISTANCE TEST POSITIVE 11 0.0107
7 MIDDLE CEREBRAL ARTERY STROKE 1 0.0088
8 INJECTION SITE DERMATITIS 1 0.0069
9 INFUSION SITE INJURY 1 0.0057
See all enriched reactions for Human Immunodeficiency Virus 1 Post-attachment Fusion Inhibitor [EPC]